Stevanato Group S.p.A. (STVN)
USD 21.38
(3.09%)
USD 21.38
(3.09%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.08 Billion EUR | 8.07% |
| 2022 | 983.7 Million EUR | 16.57% |
| 2021 | 843.9 Million EUR | 27.47% |
| 2020 | 662.03 Million EUR | 23.39% |
| 2019 | 536.53 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 237.38 Million EUR | -24.02% |
| 2024 Q2 | 260.89 Million EUR | 9.35% |
| 2023 Q1 | 237.99 Million EUR | -18.52% |
| 2023 FY | 1.06 Billion EUR | 8.07% |
| 2023 Q4 | 312.41 Million EUR | 15.11% |
| 2023 Q3 | 271.4 Million EUR | 6.31% |
| 2023 Q2 | 255.3 Million EUR | 7.27% |
| 2022 Q2 | 234.24 Million EUR | 10.46% |
| 2022 Q1 | 212.07 Million EUR | -8.82% |
| 2022 FY | 983.7 Million EUR | 16.57% |
| 2022 Q4 | 292.1 Million EUR | 19.1% |
| 2022 Q3 | 245.26 Million EUR | 4.7% |
| 2021 Q1 | 192.84 Million EUR | -6.72% |
| 2021 FY | 843.9 Million EUR | 27.47% |
| 2021 Q4 | 232.6 Million EUR | 8.42% |
| 2021 Q3 | 214.53 Million EUR | 5.18% |
| 2021 Q2 | 203.96 Million EUR | 5.76% |
| 2020 Q4 | 206.73 Million EUR | 31.63% |
| 2020 FY | 662.03 Million EUR | 23.39% |
| 2020 Q3 | 157.05 Million EUR | -2.94% |
| 2020 Q2 | 161.81 Million EUR | 18.6% |
| 2020 Q1 | 136.43 Million EUR | 0.0% |
| 2019 FY | 536.53 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alcon Inc. | 10.09 Billion USD | 89.245% |
| AptarGroup, Inc. | 3.48 Billion USD | 68.878% |
| Baxter International Inc. | 14.81 Billion USD | 92.673% |
| Becton, Dickinson and Company | 20.17 Billion USD | 94.621% |
| Bausch + Lomb Corporation | 4.14 Billion USD | 73.822% |
| Haemonetics Corporation | 1.3 Billion USD | 17.089% |
| Envista Holdings Corp | 2.56 Billion USD | 57.711% |
| ResMed Inc. | 4.68 Billion USD | 76.835% |
| Teleflex Incorporated | 2.97 Billion USD | 63.511% |
| Warby Parker Inc. | 669.76 Million USD | -62.05% |
| West Pharmaceutical Services, Inc. | 2.94 Billion USD | 63.206% |